Analysts at Goldman cut their rating on shares of MetLife, Inc. (NYSE:MET) from Buy to Neutral in their opinion released on June 04. Analysts at Atlantic Equities issued an upgrade from Neutral to Overweight for the stock, in a research note that dated back to March 26.
By watching the trading activity of corporate insiders, it will become easier to get a sense of MetLife, Inc. (NYSE:MET)’s prospects. The earliest insider trade took place on 08/27/2018. Kandarian Steven A parted with a total of 42.81 thousand shares of company at average share price of $47.03. The total for the sales was set at $2.01 million. After this transaction, the Chairman, President & CEO account balance stood at 525.54 thousand shares. The stock lost -8.78 percent since that insider sale. On 08/21/2018, Kandarian Steven A, Chairman, President & CEO, sold 85.68 thousand shares at a price per share of $46.93. This removed 4.02 million shares from the insider’s fortune and the stock saw a -8.59 percent retreat in value since the news became public. This transaction left 508.57 thousand shares in the Chairman, President & CEO account. On 05/09/2018, Director Hassell Gerald L performed a purchase transaction worth $461.8 thousand. This purchase at $46.18 each has added 10 thousand shares into the insider’s portfolio position. Meanwhile, shares have recorded -7.1 percent decrease since the transaction was reported. The insider now is left with 11.05 thousand shares remaining in the account. Townsend Christopher G, who performs the President, Asia job, sold 55.71 thousand shares for $3.02 million. The disposal occurred on 11/06/2017 was priced at $54.29 per share. The share price plunged -20.98 percent since the reporting date. Townsend Christopher G now left with a stake of 0 thousand MET stock worth $0 thousand after the insider selling.
MetLife, Inc. (MET) is expected to jump by 25.91 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $63-month high price target. This represents a whopping 48.1 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $52, which represents a return potential of 22.24 percent when compared to the closing price of the stock of $42.54 on Tuesday, October 23. The lowest price target for the stock is $44 — slightly more than 3.43 percent from MET’s current share price.
The shares are currently floating around the first support level of $41.7. Below this, the next support is placed in the zone of $40.85. Till the time, the MET stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 30.97 on daily chart, which may remain a cause for comfort. If the price breaks below $40.85 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $43.06 mark may result into a pull-back move towards $43.58 level.
MET shares dropped -0.36 points or -0.84 percent on Tuesday to $42.54 with a heavy trade volume of 6.757 million shares. After opening the session at $41.98, the shares went as high as $42.74 and as low as $41.375, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $42.1 billion and now has 989.84 million shares outstanding. MetLife, Inc. (MET) stock has lost -11.96 percent of market value in 21 trading days.
MET stock has a trailing 3-year beta of 1.24, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was $4.77 a share in the trailing twelve months. The stock’s value has fallen -15.86 percent year to date (YTD) against a decline of -20.4 percent in 12 month’s time. The company’s shares still trade -23.91 percent away from its 1-year high of $55.91 and -0.61 percent down from 52-week low of $42.80. The average consensus rating on the company is 2.4, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a sell.
Shares of MetLife, Inc. (MET) are trading at a P/E ratio of 10.02 times earnings reported for the past 12 months. The industry MET operates in has an average P/E of 14.06. Its P/E ratio went as low as 8.9X and as high as 16.53 over the 5-year span. Further, it is sporting a 0.62 on the Price-to-Sales ratio. Compare this with the industry average P/S of 1.02. 0 percent is the gross profit margin for MetLife, Inc. and operating margin sits at 8 percent. Along with this, the net profit margin is 6.4 percent.
MET will be showing off its Q3 earnings on November 01. Analysts are forecasting revenue to suffer decline of -4.1 percent to $16.1B in the next fiscal quarter, while earnings are seen soaring by nearly 22.12 percent to $1.27 per share. History has shown that shares in MetLife, Inc. have gone down on 20 different earnings reaction days and are predicted to add 0.02 percent when the company reports upcoming earnings. In last reported earnings results, it earned $1.3 per share, better than the $1.17, adjusted, expected by Thomson Reuters consensus estimate. Revenue was $21.2B, better than the $15.7B analysts expected. Earnings are estimated to increase by 35.7 percent this year, 5.28 percent next year and continue to increase by 15.1 percent annually for the next 5 years.